Event Links

Agenda

Exhibition

Sponsorship

eUpdates

Drug Discovery Technology Europe 2007

Key Themes for 2007

Large pharmaceutical companies have invested enormously over the past years in equipment for target-based drug discovery. But who has managed to integrate this fully to provide a seamless drug discovery programme?

• Improving productivity by changing processes
• Creating a seamless approach to the different drug discovery processes
• Using expensive shiny equipment in new ways to maximise RoI
• Improving decision-making at an earlier stage to reduce waste

Small pharmaceutical and biotech companies need to move compounds forwards without access to the most expensive pieces of kit.

• Case studies of successes, and what has not worked so well
• Making the right choices – earlier
• Being smart in using what you have

The advent of patient stratification and personalised medicine will change the market for drugs, whether big pharma likes it or not. How will this change the way drugs are discovered, and decisions made at the earliest stages?

Streamed sessions include

Identifying and validating truly novel targets for the next generation of drugs

• The use of systems biology: will this give more accurate results?
• Genomic vs. proteomic methods
• The use of high content and cell-based assays

Maximising the efficiency of the lead generation and optimisation processes

• What is based, high throughput screening of a massive library, of medium content screening of a more focused library?
• Specific issues for lead generation and optimisation for protein-based therapeutics
• Dealing with less-tractable targets

Discovery to development, how can we more accurately predict safety and efficacy in the clinic?

• Early biomarkers for predicting safety and efficacy
• In silico ADMET
• Developing clinically relevant animal models

Plus

Drug discovery case studies, problems, successes and lessons learned

Register

Corporate Sponsor

Designed by Jonathan Ferro | Copyright IIR 2005